Bundang Seoul National University Hospital "Advanced Regenerative Medicine Clinical Trial Approved for Glioblastoma Patients"

Bundang Seoul National University Hospital announced on the 17th that the clinical study titled "Evaluation of the Safety and Efficacy of Autologous Blood-Derived Activated Mixed Lymphocytes (CLZ-3002) Combined with Standard Chemotherapy in Newly Diagnosed Glioblastoma Patients," submitted as an advanced regenerative medicine clinical research project by the Ministry of Health and Welfare, has been approved. The principal investigator is Professor Jaeyong Kim of the Department of Neurosurgery (co-researcher Professor Gihwan Hwang of the Department of Neurosurgery).

Professor Jaeyong Kim (left) and Professor Kihwan Hwang, Department of Neurosurgery, Bundang Seoul National University Hospital.
[Photo by Bundang Seoul National University Hospital]

Glioblastoma, also known as the "worst cancer," is a rare and intractable disease occurring in about 3 to 5 people per 100,000 annually. It is known as the fastest progressing and most fatal primary brain tumor in adults. Even after standard treatments such as surgery and chemoradiotherapy, the average survival period is about 15 months, progression-free survival is 7 months, and the recurrence rate is high, highlighting the urgent need for more effective treatments and recurrence prevention strategies.

This clinical study will be conducted on patients who have undergone surgery for glioblastoma. It will evaluate the safety of cell therapy by combining standard chemotherapy with mixed immune cell therapy using the patient’s own blood, and will observe patients for over two years to explore the effect on extending survival.

Advanced regenerative medicine is a next-generation medical technology that uses cells or genes to regenerate, restore, or form body structures or functions, or to treat and prevent diseases. The Ministry of Health and Welfare selects and supports research projects with high medical necessity to provide alternatives for treating rare and intractable diseases. This study is the first clinical research on glioblastoma patients since the launch of the Ministry’s advanced regenerative medicine clinical research program and is also Bundang Seoul National University Hospital’s first advanced regenerative medicine clinical study.

Professor Jaeyong Kim stated, "We expect to confirm the safety and therapeutic effects of this new autologous activated immune cell therapy through this clinical study," adding, "We hope it will help extend the survival period and improve the quality of life for patients diagnosed with glioblastoma."

This content was produced with the assistance of AI translation services.